A Randomized, Double-blind, Vehicle Controlled, Efficacy and Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris

Trial Profile

A Randomized, Double-blind, Vehicle Controlled, Efficacy and Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris

Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Olumacostat glasaretil (Primary)
  • Indications Acne vulgaris
  • Focus Therapeutic Use
  • Acronyms CLAREOS-1
  • Sponsors Dermira
  • Most Recent Events

    • 07 Aug 2017 According to a Dermira media release, enrollment is expected to complete in the fourth quarter of 2017.
    • 06 Jan 2017 According to a Dermira media release, company initiated Phase 3 program which consists of CLAREOS-1 and CLAREOS-2 trials and are expected to enroll a total of approximately 1,400 patients ages nine and older with moderate-to-severe acne vulgaris.
    • 06 Jan 2017 According to a Dermira media release, first patient dosed in this trial. Topline results are expected in the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top